In this episode, Dr. Bradley Stein joins the show to discuss findings from his new study titled Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes, featured in the September/October issue of the Journal of Addiction Medicine.

Dr. Bradley Stein is a practicing physician and senior physician policy researcher at RAND. His research career has focused on improving access to, quality of, and outcomes from care of individuals with mental health and substance use disorders being treated in community settings. For two decades, Dr. Stein has studied the opioid crisis, serving as principal investigator for numerous federally and privately funded studies. He has published multiple peer-reviewed articles related to studies of opioid use disorder treatment, harm reduction, and the effects of state and federal policies, and he has provided Congressional testimony related to his research on multiple occasions. And his work has been covered by a range of media outlets including the Economist, Washington Post, and New York Times.

Article Link: Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes

Guest Editorial: Medicaid Unwinding May Have Substantially Disrupted Buprenorphine Treatment

In this episode, Dr. Vinit Patel sits down to discuss his new article Non-medical Mephentermine Use: A Systematic Review of Literature, as well as what exactly mephentermine is, why and how it is currently being used in non-medical settings specifically in India and South Asia, and some of the contributing factors associated with geographic disparities in non-medical mephentermine use.

Article Link: Non-medical Mephentermine Use: A Systematic Review of Literature